Diabetes

The risk for overall mortality is similar in patients with type 2 diabetes receiving glipizide, glyburide,or glimepiride monotherapy, according to the results of a retrospective cohort study, reported online March 9 in Diabetes Care. However, the findings suggest that glimepiride may be the preferred sulfonylurea in patients with underlying coronary artery disease (CAD).

Using an academic health center enterprise-wide electronic health record system, the investigators identified 11,141 patients with type 2 diabetes receiving sulfonylurea monotherapy who were at least 18 years old, with and without a history of CAD, and not taking insulin or a noninsulin injectable at baseline. Of these patients, 4279 had started monotherapy with glyburide, 4325 with glipizide, and 2537 with glimepiride.

 http://blogs.veedacr.com/Lists/Categories/Category.aspx?Name=Diabetes